Zacks Research Analysts Lower Earnings Estimates for Qiagen

Qiagen N.V. (NYSE:QGEN) – Investment analysts at Zacks Research dropped their Q4 2025 earnings per share estimates for shares of Qiagen in a research report issued to clients and investors on Thursday, January 22nd. Zacks Research analyst Team now forecasts that the company will post earnings of $0.62 per share for the quarter, down from their prior forecast of $0.62. The consensus estimate for Qiagen’s current full-year earnings is $2.26 per share. Zacks Research also issued estimates for Qiagen’s Q3 2026 earnings at $0.67 EPS, Q4 2026 earnings at $0.63 EPS, Q1 2027 earnings at $0.68 EPS, Q2 2027 earnings at $0.70 EPS and Q3 2027 earnings at $0.72 EPS.

A number of other research analysts have also recently weighed in on QGEN. Deutsche Bank Aktiengesellschaft cut shares of Qiagen from a “buy” rating to a “hold” rating and boosted their target price for the company from $52.00 to $54.00 in a research note on Thursday. Wall Street Zen cut Qiagen from a “buy” rating to a “hold” rating in a research note on Saturday, January 10th. Citigroup lowered shares of Qiagen from a “buy” rating to a “neutral” rating and cut their price target for the company from $57.89 to $52.63 in a research report on Thursday, December 11th. Weiss Ratings reiterated a “hold (c)” rating on shares of Qiagen in a research report on Monday, December 29th. Finally, UBS Group reissued a “neutral” rating on shares of Qiagen in a research note on Wednesday. Two research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $53.04.

Qiagen Price Performance

Shares of NYSE:QGEN opened at $54.27 on Friday. Qiagen has a fifty-two week low of $39.61 and a fifty-two week high of $57.81. The company’s 50-day moving average is $48.71 and its 200 day moving average is $49.49. The company has a debt-to-equity ratio of 0.45, a quick ratio of 2.30 and a current ratio of 2.60. The company has a market capitalization of $11.46 billion, a P/E ratio of 28.02, a price-to-earnings-growth ratio of 2.56 and a beta of 0.66.

Qiagen (NYSE:QGEN) last issued its quarterly earnings results on Thursday, November 6th. The company reported $0.64 EPS for the quarter, topping analysts’ consensus estimates of $0.61 by $0.03. Qiagen had a return on equity of 14.80% and a net margin of 19.58%.The business had revenue of $532.58 million for the quarter, compared to analyst estimates of $525.68 million. During the same period last year, the company posted $0.60 earnings per share. Qiagen’s quarterly revenue was up 6.2% compared to the same quarter last year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in QGEN. Massachusetts Financial Services Co. MA boosted its holdings in Qiagen by 1.1% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 24,205,881 shares of the company’s stock worth $1,088,538,000 after acquiring an additional 264,921 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Qiagen by 1.9% in the 3rd quarter. Vanguard Group Inc. now owns 9,424,809 shares of the company’s stock worth $420,401,000 after purchasing an additional 172,062 shares during the last quarter. Amundi boosted its stake in Qiagen by 4.4% in the 3rd quarter. Amundi now owns 4,290,273 shares of the company’s stock worth $201,471,000 after purchasing an additional 181,509 shares in the last quarter. Boston Partners purchased a new stake in Qiagen during the 3rd quarter valued at about $179,450,000. Finally, Norges Bank bought a new stake in Qiagen during the 2nd quarter valued at about $158,728,000. Institutional investors own 70.00% of the company’s stock.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.